Aktienanalyse zu Globus Medical Inc (GMED)GMEDGlobus Medical Inc

Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Currently, Globus Medical Inc (GMED) is trading at $81.41, which is close to the analyst price target of $82 from UBS. The stock has a high RSI of 72.306, indicating it may be overbought, while the forward P/E ratio of 13.87 suggests it is reasonably valued compared to its growth prospects. However, insider selling has increased by 389.20%, which raises concerns about management confidence. Given these mixed signals, it may be prudent to hold rather than buy at this time.

13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.